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Background: Although recent studies have shown the utility of miR-203 as a cancer-relevant biomarker, the
validated clinical significance of miR-203 in HCC remains obscure. The aim of the present study was to evaluate the
relationship between miR-203 expression and clinicopathological features in HCC patients.
Methods: MiR-203 expression in 95 formalin-fixed, paraffin embedded (FFPE) HCC tissues and their paired adjacent
non-cancerous tissues was evaluated by quantitative reverse transcription polymerase chain reaction (qRT-PCR).
Simultaneously, expression of miR-203 and its correlation with a variety of clinicopathological parameters and
patient recurrence was analyzed.
Results: The relative level of miR-203 was 1.1651 ± 0.70378 in HCC tissues, significantly lower than its expression in
the corresponding adjacent non-cancerous liver tissues (2.2408 ± 0.75351, P < 0.001). The area under curve (AUC) of
low miR-203 expression to diagnose HCC was 0.85 (95 % CI: 0.796 ~ 0.904, P = 0.027) at a cut-off value 1.99 evaluated
by the median expression of miR-203 in all tissues, including HCC and normal liver tissues. Expression of miR-203 was
negatively correlated to metastasis (r = −0.254, P = 0.013), clinical tumor nodes metastasis (TNM) stage (r = −0.300,
P = 0.003), nm23 expression (r = −0.292, P = 0.004), p21 expression (r = −0.223, P = 0.030), microvessel density
(MVD)(r = −0.206, P = 0.045) and was positively correlated to cirrhosis (r = 0.487, P < 0.001). Additionally, the
recurrent time of lower miR-203 expression group was 57.949 ± 4.184 months, slightly longer than that in the
high expression group (54.682 ± 2.591 months), however, no significant difference was noted (Chi-square = 0.206,
P = 0.650).
Conclusions: MiR-203 plays a vital role in the carcinogenesis and progression of HCC, which makes itself as a
predictor for the deterioration of HCC. Furthermore, miR-203 may become a new target for molecular therapy in
HCC.
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Hepatocellular carcinoma (HCC), with a 5-year survival
rate of only 9 %, is the fifth most frequent malignancy
and the third most common cause of cancer mortality
worldwide [1–3]. The incidence of HCC is higher in
male compared to the female. Among all cases, over 80 %
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tially in Europe and the United States. Studies have shown
that HCC resulted in 650,000 or more deaths per year all
over the world, among which, three quarters occurred in
East Asian countries [4, 5]. Multiple etiological factors
contribute to the carcinogenesis and progression of HCC,
for instance, infection of hepatitis B virus (HBV) or hepa-
titis C virus (HCV) and long-term exposure to some
chemical agents (alcohol or aflatoxin B1) [6–9]. During
the process of HCC development, gene expression, cell
apoptosis, cell migration, vaso-invasion and capsule in-
filtration play essential roles [10]. HCC patients withdistributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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dence of recurrence and a dismal outcome [11]. It
arouses our interest to improve the prognosis, to en-
hance the survival and to reduce the recurrence rate of
HCC. Therefore, it is of vital importance to identify
reliable biomarkers for the prediction of HCC and its
recurrence along with to elucidate its role in HCC
treatment.
MicroRNAs (miRNAs), an abundant class of endogen-
ous, small, non-coding RNAs, have been identified as
gene expression regulators [12, 13]. By binding to par-
tially complementary or fully complementary sites within
the 3′-untranslated region (UTR) of target messenger
RNAs (mRNAs), miRNAs can trigger the translational
repression, or deadenylation and degradation of mRNA
[14, 15]. Recent studies have implicated that miRNAs
are involved in a wide range of important biologic
processes and essential tumorigenesis, including cellu-
lar growth and differentiation, developmental timing,
modulation of host response to viral infection, prolifer-
ation, invasion and apoptosis [9, 16, 17].
Previous studies have indicated that microRNA-203
(miR-203) exhibited significantly down-regulated expres-
sion in prostate cancer [18], hematopoietic malignancy
[19], colon cancer [20]. Other studies have shown that
the low level expression of miR-203 played an important
role in cell proliferation in the human head and neck
squamous cell carcinoma, chronic myelogenous leukemia
and B cell leukemia [21]. Concerning HCC, one study
based on liver cancer cell lines identified that miR-203
was a tumor-suppressor gene silenced through tumor-
specific DNA methylation in HCC [22]. Another study
found that expression of miR-203 was low in tumor
tissues of patients with post-LT (liver transplantation)
HCC with recurrence compared to those in patients with
non-recurrence [23]. However, aberrant expression of
miR-203 between HCC and the paired non-cancerous
liver tissues, as well as its clinicopathological significance
in HCC has not been documented. Therefore, we aimed
to quantify miR-203 expression in HCC tissues and com-
pare it with the matched adjacent normal tissues in order
to investigate the correlation between miR-203 expression
and clinicopathological features, especially metastasis and
recurrence in HCC patients.
Results
Characteristics of the HCC patients
The clinicopathological features of 95 HCC patients
were shown in Table 1. All patients only underwent liver
resection and nobody received any local ablative therapy
(percutaneous ethanol injection PEI, radiofrequency
ablation RFA), transhepatic arterial chemotherapy and
embolization (TACE) or transhepatic arterial radioem-
bolization (TARE) before liver resection. The majorityof patients had well-differentiated or moderate-
differentiated HCC while 29 patients (30.53 %) were
poor-differentiated. Tumor sizes ranged from 1 to 11 cm
(mean size, 6.4 cm). Vascular invasion was presented in 36
patients (37.89 %) while 50 patients presented with tumor
capsule infiltration (52.63 %). Thirty-eight patients (40 %)
had elevated serum alpha fetal protein (AFP) levels
(400 ng/ml). The mean time of follow-up was 33.13 ±
1.71 months (range: 2.68–68.00 months). Of the 70HCC
patients included in the follow-up, 59 had recurrent
tumors and 11 were dead or censored at the end of
follow-up.
Value of miR-203 in the diagnosis of HCC
There was a significant difference of relative miR-203
expression between HCC and the paired adjacent non-
cancerous liver tissues. The relative level of miR-203
was 1.17 ± 0.70 in HCCs, significantly lower than that
of the adjacent non-cancerous liver tissues (2.24 ± 0.75,
P < 0.001, Fig. 1a, b). Additionally, we conducted ROC
curve to identify the diagnostic role of miR-203 in
HCC. The area under curve (AUC) of miR-203 was
0.85 (95 % CI: 0.796 ~ 0.904, P = 0.027, Fig. 1c) at a cut-
off value of 1.99.
The relationship between miR-203 expression and
clinicopathological parameters of HCC
With respect to the association between miR-203 ex-
pression and clinicopathological parameters of HCC, the
following results were obtained. The relative expression
of miR-203 in HCC patients with tumor larger than 5 cm
(1.23 ± 0.73) was remarkably higher in comparison with
those whose tumor were smaller than 5 cm (0.9061 ±
0.50149, P = 0.034). Also, the relative expression of miR-
203 in HCC patients with single tumor nodes (1.30 ± 0.77)
was prominently higher than those with multiple tumor
nodes (1.01 ± 0.59, P = 0.046). Compared to those with
metastasis (1.00 ± 0.60), the level of miR-203 was higher in
those HCC patients without metastasis (1.34 ± 0.77, P =
0.021). When compared with HCC patients of advanced
stages (III and IV, 1.05 ± 0.63), the relative expression
of miR-203 in early stages patients (I and II, 1.56 ± 0.79,
P = 0.002) was notably increased. Besides, the relative
expression of miR-203 in HCC patients without cirrho-
sis (1.49 ± 0.72) was obviously higher than those with
cirrhosis (0.80 ± 0.47, P < 0.001). In association with
nm23, HCC patients with negative expression of nm23
(1.60 ± 0.82) had a higher level of miR-203 than those
with positive expression (1.05 ± 0.63, P = 0.002). As for
the relationship with the expression of p21, negative ex-
presser had a noticeably higher level of miR-203 (1.28 ±
0.73) than the positive one (0.96 ± 0.62, P =0.035).
Moreover, miR-203 level in VEGF negative HCC pa-
tients was higher (1.43 ± 0.82), compared with VEGF
Table 1 Relationship between miR-203 expression and clinicopathological features in HCC
Clinicopathological Features N miRNA-203 relevant expression (2-ΔCq)
Mean ± SD t P
Tissue Adjacent non-cancerous liver 95 2.2408 ± 0.75351 10.170 <0.001
HCC 95 1.1651 ± 0.70378
Age <50 49 1.0951 ± 0.72640 1.000 0.320
≥50 46 1.2396 ± 0.67884
Gender male 75 1.1163 ± 0.70032 −1.313 0.192
female 20 1.3480 ± 0.70405
Differentiation well 6 1.1717 ± 0.53229 0.804a 0.451
moderate 60 1.2305 ± 0.73598
poor 29 1.0283 ± 0.66507
Size <5 cm 18 0.9061 ± 0.50149 −2.208 0.034
≥5 cm 77 1.2256 ± 0.73265
Tumor nodes single 52 1.2960 ± 0.76903 2.026 0.046
multiple 43 1.0067 ± 0.58613
Metastasis - 46 1.3363 ± 0.77316 2.353 0.021
+ 49 1.0043 ± 0.59589
Clinical TNM stage I-II 22 1.5600 ± 0.79292 3.141 0.002
III-IV 73 1.0460 ± 0.63345
Portal vein tumor embolus - 63 1.2387 ± 0.76142 1.440 0.153
+ 32 1.0200 ± 0.55646
Vaso-invasion - 59 1.1810 ± 0.76883 0.282 0.779
+ 36 1.1389 ± 0.59126
Tumor capsular infiltration With complete capsule 45 1.1549 ± 0.75314 −0.133 0.895
Infiltration or no capsule 50 1.1742 ± 0.66383
HCV - 63 1.1073 ± 0.71115 −1.124 0.264
+ 32 1.2788 ± 0.68580
HBV - 17 1.2624 ± 0.51125 0.627 0.532
+ 78 1.1438 ± 0.74014
AFP - 41 1.1173 ± 0.69725 −0.629 0.531
+ 38 1.2184 ± 0.73104
Cirrhosis - 50 1.4912 ± 0.72123 5.436 0.000
+ 45 0.8027 ± 0.47296
MTDH - 38 1.1561 ± 0.69533 0.162 0.872
+ 51 1.1320 ± 0.69657
nm23 - 20 1.5965 ± 0.82139 3.237 0.002
+ 75 1.0500 ± 0.62628
p53 - 40 1.1412 ± 0.69109 −0.280 0.780
+ 55 1.1824 ± .71871
p21 - 62 1.2758 ± 0.72648 2.142 0.035
+ 33 0.9570 ± 0.61683
VEGF - 25 1.4252 ± 0.82009 2.196 0.031
+ 70 1.0721 ± 0.63841
Ki-67 LI Low 47 1.1726 ± 0.76271 0.102 0.919
High 48 1.1577 ± 0.64897
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Table 1 Relationship between miR-203 expression and clinicopathological features in HCC (Continued)
MVD Low 47 1.1900 ± 0.69824 0.340 0.734
High 48 1.1406 ± 0.71570
N number, SD standard deviation, TNM tumor node metastasis, HBV hepatitis B virus, HCV hepatitis C virus, AFP alpha fetal protein, MTDH metadherin, VEGF
vascular endothelial growth factor, LI labeling index, MVD microvessel density
aANOVA test was performed
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Table 1). Meanwhile, we conducted a further analysis
using Spearman correlation test, the consistent relation-
ship between the expression of miR-203 and the clinico-
pathological parameters of HCC were listed as follows:
metastasis (r = −0.254, P = 0.013), TNM (r = −0.300, P =
0.003), cirrhosis (r = 0.487, P < 0.001), nm23 (r = −0.292,
P= 0.004), p21 (r=−0.223, P= 0.030) and MVD (r=−0.206,
P= 0.045). Additionally, the AUC of miR-203 and metasta-
sis was 0.647 (95 % CI: 0.536 ~ 0.757, P = 0.014, Fig. 3a),
and the AUC of miR-203 and TNM was 0.705 (95 % CI:
0.575 ~ 0.834, P = 0.004, Fig. 3b). However, no association
was found between miR-203 expression and other clinico-
pathological features, such as age, gender, tumor differen-
tiation grades, portal vein tumor embolus, vascular
invasion, tumor capsular infiltration, HCV or HBV infec-
tion condition, AFP, metadherin (MTDH), p53, vascular
endothelial growth factor (VEGF) and ki-67 expression.
As for tumor size and tumor nodes, expression of miR-
203 between each two groups was significantly different,
respectively. However, no correlation was found between
miR-203 and tumor size or tumor nodes by Spearman
analysis.
Role of miR-203 expression in recurrence of HCC
Among all the 95 patients, we had a successful follow-
up of 70 patients, among which 52 had low miR-203
expression (lower than the median level of 0.97) while
18 had high miR-203 expression. As for time to recurrence,
low miR-203 expression group was 57.949 ± 4.184 months,
while the high expression group was 54.682 ± 2.591 months.
No significant difference of recurrent time was found be-
tween the low and high miR-203 groups (Chi-square =
0.206, P = 0.650).
Discussion
Up till now, there have been only three studies that ex-
plored the role of miR-203 in HCC [22–24]. Among the
available articles, Wang et al. [24] only evaluated expres-
sion of miR-203 in HepG2 cells by Western blot assay
without using clinical HCC specimens. Furuta et al. [22]
examined a total of 19 liver cancer cell lines and 41 fro-
zen primary tumor samples with their corresponding
non-tumorous tissues and confirmed that expression of
miR-203 was silenced through tumor-specific DNA
methylation in HCC. Chen et al. [23] confirmed that ex-
pression of miR-203 was lower in tumor tissues. Chenet al. reported that miR-203 expression was measured in
66 HCC patients who underwent orthotopic deceased
donor liver transplantation. However, the 95 HCC pa-
tients who were selected into the current study received
no additional treatment including chemoradiotherapy,
liver transplantation or ablation. Of note, our current
study collected and compared 95 HCC samples with
their paired adjacent non-cancerous tissues twice more
than the 41 samples examined in the research of Furuta
et al. [22]. Of particular note, these paired samples elimi-
nated the individual differences and achieved better
comparability. As a result, significantly lower level of
miR-203 expression was found in HCC tissues compared
with adjacent non-cancerous tissues. The ratio of miR-
203 in HCC tissues to that in non-cancerous tissues was
0.52. Furthermore, the AUC of 0.85, nearly 0.9 from
ROC analysis demonstrated that miR-203 had a specific
diagnostic value for HCC. Combined with the literatures,
our current finding strongly indicated that miR-203 could
be regarded as a tumor-suppressor in HCC.
We primarily revealed that expression of miR-203 was
relevant to the deterioration of HCC by analyzing the
association between miR-203 expression and clinico-
pathological parameters. First of all, miR-203 was down-
regulated in HCC tissues with multiple tumor nodes and
with metastasis, as compared to their corresponding
traits respectively. Furthermore, miR-203 expression was
negatively related to HCC progression. MiR-203 reduced
evidently when there appeared cirrhosis or when HCC
developed into advanced stage. In addition, expression
of miR-203 was down-regulated in HCC tissues where
nm23 and p21 were positive. Above results indicated
that low level of miR-203 was closely associated with
factors of HCC development, such as metastasis, mul-
tiple tumor nodes and late clinical stages. However,
miR-203 was of higher level in HCC tissues whose
tumor sizes were over 5 cm. Under normal conditions,
we regard larger size tumors as the more aggressive
ones. Here, the result was contradictory. MiR-203 may
play more important roles in tumor cell invasion and
metastasis than tumor cell growth. However, this hy-
pothesis needs further in vitro and in vivo experiments
to confirm in the future. For the relationship between
miR-203 level and patient recurrence, although patients
with lower level of miR-203 showed a longer time of re-
currence than the higher level patients, no statistical sig-
nificance was noted (Fig. 4). Cohorts with larger patient
Fig. 1 Expression of miR-203 in adjacent non-cancerous liver and
HCC tissues. Quantitative real-time PCR was performed to detect the
expression of miR-203. a: Relative expression of miR-203 in adjacent
non-cancerous liver and HCC tissues (dot plots with lines linking
each pairs). b: The difference of relevant miR-203 expression between
adjacent non-cancerous liver and HCC tissues. ***P < 0.001. c: ROC
curve of miR-203 expression to distinguish HCC from non-cancerous
liver. The area under curve (AUC) of miR-203 was 0.85 (95 % CI: 0.796 ~
0.904, P = 0.027) at a cut-off value of 1.99. Error bars represented
standard deviation (SD). The statistical analysis was performed with
Student’s t-test (a and b)
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miR-203 and recurrence in HCC.
MVD, VEGF and MTDH are factors related to angio-
genesis, which play a vital role in tumor growth and pro-
gression. Among them, MTDH was found to have partly
complementary sequences with miR-203 with several
prediction software (miRbase, Tarbase, targetScan and
miRanda). Li et al. [25] have demonstrated that by nega-
tively regulating Akt2 protein expression, miR-203 re-
versed chemoresistance in p53-mutated colon cancer
cells where MTDH was involved. Zhu et al. [26] pointed
out that miR-203 down-regulated vascular endothelial
growth factor alpha (VEGFA) expression by directly
targeting its 3′-untranslated region in human cervical
cancer. Nevertheless, we found no significant correl-
ation between miR-203 and MTDH or VEGF in HCC,
only MVD showed a significant correlation with miR-
203 (r = −0.20607 P = 0.045). Other cohort with more
patients involved and in vitro study are required to exam-
ine the potential role of MTDH as a target of miR-203. As
Furuta et al. [22] suggested in his article, the silencing of
miR-203 contributed to the pathogenesis of HCC by acti-
vating of ATP binding cassette E1 (ABCE1).
And Wang et al. [24] revealed that low expression of
miR-203 dedicated to the progression of HCC via target-
ing survivin. All these findings strongly support our
result that expression of miR-203 was relevant to the de-
terioration of HCC via different pathways.
Conclusion
In accordance with previous researches, our current
study strongly prompts that miR-203 is a tumor-
suppressive miRNA, contributing to the carcinogenesis
and deterioration of HCC. Expression of miR-203 can be
a diagnostic biomarker for HCC. To investigate and
identify the function of miR-203 in HCC, as well as to
regard miR-203 as a new target for HCC treatment, fur-
ther in vitro and in vivo studies are needed in future.
Methods
Patients and tissue samples
A total number of 95 HCC patients (75 males and 20
females, with a mean age of 52 years old, ranged from
Fig. 2 The relationship between miR-203 expression and clinicopathological parameters of HCC. a: Tumor size, (b): Tumor nodes, (c): metastasis
status, (d): clinical TNM stage, (e): cirrhosis, (f): nm23, (g): p21, (h): VEGF. The data were representative of two independent experiments. Error bars
represented SD. * P <0.05, ** P <0.01, *** P <0.001 by Student’s t-test (a-g)
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Fig. 3 Diagnostic significance of different parameters on HCC. a. The ROC curve of miR-203 for discriminating metastasis from non-metastasis in
HCC patients. The AUC of miR-203 and metastasis was 0.647 (95 % CI: 0.536 ~ 0.757, P = 0.014) at a cut off value of 1.52. b. ROC curve of miR-203
expression to distinguish advanced clinical TNM stage from early TNM stage in patients with HCC. The AUC of miR-203 and TNM was 0.705 (95 %
CI: 0.575 ~ 0.834, P = 0.004) at a cut-off value of 1.57. The cut off values were measured according to the median expression of miR-203 in HCC
tissues. Error bars represented SD. Significance of difference between two groups was analyzed by Student’s t test (a and b)
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Affiliated Hospital of the Guangxi Medical University
(Nanning Guangxi, China) between March, 2010 and
December, 2011, were selected for this current study.
Their formalin-fixed, paraffin embedded (FFPE) tumor
tissues and adjacent non-cancerous liver tissues were
retrospectively evaluated. The clinicopathological param-
eters of patients including age, gender, differentiation,
tumor size, tumor nodes, metastasis and clinical TNM
stages, the presence or absence of portal vein tumor
embolus, vaso-invasion, capsular infiltration and cirrho-
sis, and other biomarkers such as serum AFP level,
expression of metadherin (MTDH), nm23, p53, p21, vas-
cular endothelial growth factor (VEGF) and microvesselFig. 4 Recurrence free survival of HCC patients according to
miR-203 levels. There was no significant association between
miR-203 expression and recurrence free survival in patients with
HCC (P = 0.650). Error bars represented SD. Survival difference
according to miR-203 expression was analyzed by the log-rank testdensity (MVD). The clinical TNM stage is the most
common system for staging to employ the TNM classifi-
cation. A “T” score is based upon the size and/or extent
of invasion. The “N” score indicates the extent of lymph
node involvement. The “M” score indicates whether
distant metastasis is present. All these features were
summarized in Table 1. The Ethical Committee of First
Affiliated Hospital, Guangxi Medical University, China
approved the current research, and informed consent
was obtained from all participating patients. Related re-
search was conducted in accordance with the Helsinki
Declaration. All samples were reviewed and diagnosed
by two independent pathologists.
RNA isolation and quantification of miR-203
Extraction and normalization of RNAs along with miR-
NAs by using the miRNeasy FEPE Kit (QIAGEN, KJ
Venlo, Netherlands) were performed as described previ-
ously [27–30]. RNA concentrations were determined by
NanoDrop 2000 (Wilmington, DE, USA). A combination
of RUN6B and RUN48 was the housekeeping gene for
detection of miR-203 expression in HCC FFPE tissues
[27, 28]. The primers for miR-203, RNU6B and RNU48,
were included in TaqMan®MicroRNAAssays (4427975,
Applied Biosystems, Life Technologies, Grand Island,
NY, USA). Sequence of miRNA and references used in
the paper are as follows: miR-203 (Applied Biosystems
Cat. No. 4427975–000507): GUGAAAUGUUUAGGA
CCACUAG; RNU6B (Applied Biosystems Cat. No.
4427975–001093): CGCAAGGAUGACACGCAAAUUC
GUGAAGCGUUCCAUAUUUUU; RNU48 (Applied
Biosystems Cat. No. 4427975–001006): GAUGACCCC
AGGUAACUCUGAGUGUGUCGCUGAUGCCAUCA
CCGCAGCGCUCUGACC. The reverse primers were also
used for reverse transcription with TaqMan®MicroRNA
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plied Biosystems, Life Technologies) in a total volume of
10 μL. Real-time qPCR for miRNA was performed with
Applied Biosystems PCR7900. The miR-203 abundance in
each sample was normalized to its references. The expres-
sion of miR-203 in the FFPE experiments was calculated
with the formula 2-Δcq [27–31].
Statistical analysis
SPSS 20.0 (Munich, Germany) was used for statistical
analysis. Quantitative variables were presented as means
± standard deviation (SD). Significance of difference
between two groups was analyzed by Student’s t test.
Significance of difference within three groups (we di-
vided differentiation condition into three groups) was
analyzed by One-way analysis of variance (ANOVA) test.
Correlation between miR-203 expression and clinico-
pathological parameters was detected by using Spear-
man. Effectiveness of miR-203 to distinguish HCC from
non-cancerous liver tissues was generated by receiver
operating characteristic (ROC) curves. Recurrence ana-
lysis was estimated by the Kaplan–Meier method, and
the log-rank test was used to compare the recurrence
between groups. When P-value was less than 0.05, calcu-
lated by two-tailed test, it was considered as statistically
significant.
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